Kura Oncology, Inc.

KURA

$11.73

Updated: 22/09/2026, 23:43:51

Market Cap

$1.04B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for KURA

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

USD

NASDAQ

CEO: Troy Wilson

Employees: 260

https://kuraoncology.com

Asset Summaries

Latest generated summaries for KURA

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for KURA.

Share price: $11.73
Market cap: $1.04B
Exchange: NASDAQ
Currency: USD
CEO: Troy Wilson
Employees: 260
IPO date: 16/09/2015
Beta: 0.381
Last dividend: $0.00
Day range: $11.58 – $11.99
52-week range: $7.36 – $13.90
1-day performance: 1.12%
1-year performance: 59.42%
Current drawdown (1Y): -15.61%
CIK: 0001422143
CUSIP: 50127T109
ISIN: US50127T1097
Created: 07/12/2025, 04:59:42
Last update: 22/09/2026, 23:43:51

Track Kura Oncology, Inc. with an AI analyst

See which prediction-market events move KURA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to KURA from your Railway `news_articles` table.

Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript

Seeking Alpha • STOCK • 12/06/2026, 21:02:09

Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript

Seeking Alpha • STOCK • 04/06/2026, 04:52:12

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

GlobeNewsWire • STOCK • 26/05/2026, 08:02:00

Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 23:00:47

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 13/05/2026, 02:20:46

Kura Oncology Q1 Earnings Call Highlights

MarketBeat • STOCK • 12/05/2026, 23:10:05

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research • STOCK • 12/05/2026, 20:16:10

Kura Oncology Reports First Quarter 2026 Financial Results

GlobeNewsWire • STOCK • 12/05/2026, 18:02:00

Kura Oncology to Report First Quarter 2026 Financial Results

GlobeNewsWire • STOCK • 05/05/2026, 09:30:00

Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research • STOCK • 30/04/2026, 13:01:39

Kura Oncology: Poised For A Lift With Combinations

Seeking Alpha • STOCK • 20/04/2026, 14:42:43

KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data

Zacks Investment Research • STOCK • 20/04/2026, 13:26:12